BRAF and cancer: The pathways identified in the enrichment analysis of the 37 proteins at high level in the poor-response group were cancer-associated, including high-kinase activity BRAF mutant, RAF1 mutant, paradoxical activation of RAF by kinase-inactive BRAF, downstream RAS mutant, moderate kinase activity BRAF mutant, RAS mutants, BRAF and RAF1 fusion, and oncogenic MAPK signaling (Table 5).